Skip to main content

Insulet (PODD) Gets a Buy from BTIG

Tipranks - Tipranks - Sat Feb 21, 11:16AM CST

In a report released on February 18, Marie Thibault from BTIG maintained a Buy rating on Insulet, with a price target of $380.00.

President's Day Sale - 70% Off

According to TipRanks, Thibault is an analyst with an average return of -12.6% and a 33.53% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Ceribell, Inc., and Boston Scientific.

In addition to BTIG, Insulet also received a Buy from Goldman Sachs’s David Roman in a report issued today. However, yesterday, TD Cowen maintained a Hold rating on Insulet (NASDAQ: PODD).

See Insiders’ Hot Stocks on TipRanks >>

Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $706.3 million and a net profit of $87.6 million. In comparison, last year the company earned a revenue of $543.9 million and had a net profit of $77.5 million

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2025, Frederick Wayne A.I. , a Director at PODD sold 1,851.00 shares for a total of $542,509.59.

Read More on PODD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).